Document is current
Any future updates will be listed below
-
Authors
LaFleur, Martin W.
Nguyen, Thao H. https://orcid.org/0000-0002-2767-0528
Coxe, Matthew A.
Miller, Brian C.
Yates, Kathleen B. https://orcid.org/0000-0002-7383-5573
Gillis, Jacob E.
Sen, Debattama R.
Gaudiano, Emily F.
Al Abosy, Rose https://orcid.org/0000-0001-5400-1306
Freeman, Gordon J.
Haining, W. Nicholas https://orcid.org/0000-0001-7871-3762
Sharpe, Arlene H. https://orcid.org/0000-0002-9736-2109
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (U19AI133524)
U.S. Department of Health & Human Services | NIH | National Center for Advancing Translational Sciences (KL2 TR002542)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P50CA101942)
- License Information
-
More Information
Article History
Received: 11 February 2019
Accepted: 29 July 2019
First Online: 16 September 2019
Competing interests
: A.H.S. has patents on the PD-1 pathway licensed by Roche/Genentech and Novartis, consults for Novartis, is on the scientific advisory boards for Surface Oncology, Sqz Biotech, Elstar Therapeutics, Elpiscience, Selecta and Monopteros and has research funding from Merck, Novartis, Roche, Ipsen, UCB and Quark Ventures. W.N.H. has a patent application on T cell exhaustion-specific enhancers held by the Dana-Farber Cancer Institute and now is employed by Merck. W.N.H. is also a founder of Arsenal Biosciences. A.H.S. and W.N.H. have a patent application on PTPN2 as a therapeutic target held/submitted by the Dana-Farber Cancer Institute. G.J.F. has a consulting or advisory role for Novartis, Lilly, Roche/Genentech, Bristol-Myers Squibb, Bethyl Laboratories, Xios Therapeutics, Quiet Therapeutics and Seattle Genetics; patents, royalties or other intellectual property from Novartis, Roche/Genentech, Bristol-Myers Squibb/Medarex, Amplimmune/Astrazeneca, Merck, EMD Serono and Boehringer Ingelheim and research funding from Bristol-Myers Squibb. The remaining authors declare no competing interests.
